Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury

American Journal of Respiratory Cell and Molecular Biology

Volumn 51, Issue 2, 2014, Pages 223-228

  Moreno Vinasco, Liliana ^a   Quijada, Hector ^b   Sammani, Saad ^a   Siegler, Jessica ^a   Letsiou, Eleftheria ^a   Deaton, Ryan ^a   Saadat, Laleh ^a   Zaidi, Rafe S ^a   Messana, Joe ^a   Gann, Peter H ^c   Machado, Roberto F ^a   Ma, Wenli ^b   Camp, Sara M ^b   Wang, Ting ^b   Garcia, Joe G N ^a,b,c  

^a Department of Medicine   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; FK 866; Nicotinamide phosphoribosyltransferase; Polymorphonuclear neutrophil; Vascular endothelium

Indexed keywords

APOPTOSIS; FK-866; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLYMORPHONUCLEAR NEUTROPHIL; VASCULAR ENDOTHELIUM;

ACRYLAMIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BRONCHOALVEOLAR LAVAGE FLUID; CASPASE 3; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INFLAMMATION MEDIATORS; LUNG; MICE; MICE, INBRED C57BL; NAD; NEUTROPHILS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, ADULT; VENTILATOR-INDUCED LUNG INJURY;

EID: 84905499872     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0519OC     Document Type: Article

References (26)

1. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, Easley RB, McVerry BJ, Tuder RM, Standiford T, et al. Pre-b-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005;171:361-370.
2. Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC. Pre-b-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. Crit Care Med 2007;35:1290-1295.
3. Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG. Pre-b-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 2005;70:142-151.
4. Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O, et al. Visfatin/pbef/nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res 2010;42:268-273.
5. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. Visfatin/pbef and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010;8:12-28.
6. Pillai VB, Sundaresan NR, Kim GH, Samant S, Moreno-Vinasco L, Garcia JG, Gupta M. Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am J Physiol Heart Circ Physiol 2013;304:H415-H426.
7. Luk T, Malam Z, Marshall JC. Pre-b cell colony-enhancing factor (pbef)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-816.
8. Hong SB, Huang Y, Moreno-Vinasco L, Sammani S, Moitra J, Barnard JW, Ma SF, Mirzapoiazova T, Evenoski C, Reeves RR, et al. Essential role of pre-b-cell colony enhancing factor in ventilator-induced lung injury. Am J Respir Crit Care Med 2008;178:605-617.
9. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of fk866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008;26:45-51.
10. Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nussler V, Hasmann M. Chemopotentiating effects of a novel nad biosynthesis inhibitor, fk866, in combination with antineoplastic agents. Eur J Med Res 2006;11:313-321.
11. Hasmann M, Schemainda I. Fk866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-7442.
12. Esposito E, Impellizzeri D, Mazzon E, Fakhfouri G, Rahimian R, Travelli C, Tron GC, Genazzani AA, Cuzzocrea S. The nampt inhibitor fk866 reverts the damage in spinal cord injury. J Neuroinflammation 2012;9:66.
13. Moschen AR, Gerner R, Schroll A, Fritz T, Kaser A, Tilg H. A key role for pre-b cell colony-enhancing factor in experimental hepatitis. Hepatology 2011;54:675-686.
14. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, Pearse D, Tuder RM, Garcia JG. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004;169:1245-1251.
15. Mirzapoiazova T, Moitra J, Moreno-Vinasco L, Sammani S, Turner JR, Chiang ET, Evenoski C, Wang T, Singleton PA, Huang Y, et al. Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury. Am J Respir Cell Mol Biol 2011;44:40-52.
16. Meyer NJ, Huang Y, Singleton PA, Sammani S, Moitra J, Evenoski CL, Husain AN, Mitra S, Moreno-Vinasco L, Jacobson JR, et al. Gadd45a is a novel candidate gene in inflammatory lung injury via influences on akt signaling. FASEB J 2009;23:1325-1337.
17. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, Samant S, Ravindra PV, Isbatan A, Gupta MP. Exogenous nad blocks cardiac hypertrophic response via activation of the sirt3-lkb1-amp-activated kinase pathway. J Biol Chem 2010;285:3133-3144.
18. Klapczynski M, Gagne GD, Morgan SJ, Larson KJ, Leroy BE, Blomme EA, Cox BF, Shek EW. Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models. J Pathol Inform 2012;3:20.
19. Mekontso Dessap A, Voiriot G, Zhou T, Marcos E, Dudek SM, Jacobson JR, Machado R, Adnot S, Brochard L, Maitre B, et al. Conflicting physiological and genomic cardiopulmonary effects of recruitment maneuvers in murine acute lung injury. Am J Respir Cell Mol Biol 2012;46:541-550.
20. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-b cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318-1327.
21. Montecucco F, Bauer I, Braunersreuther V, Bruzzone S, Akhmedov A, Luscher TF, Speer T, Poggi A, Mannino E, Pelli G, et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal 2013;18:630-641.
22. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to nad. PLoS ONE 2008;3:e2267.
23. Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov A, Mostoslavsky R, Alt FW, De Smedt T, Leo O. Intracellular nad levels regulate tumor necrosis factor protein synthesis in a sirtuindependent manner. Nat Med 2009;15:206-210.
24. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damas JK, Haaland T, Loberg EM, Arntsen B, Birkeland K, et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95:3039-3047.
25. Cheng Q, Dong W, Qian L, Wu J, Peng Y. Visfatin inhibits apoptosis of pancreatic beta-cell line, min6, via the mitogen-activated protein kinase/phosphoinositide 3-kinase pathway. J Mol Endocrinol 2011;47:13-21.
26. Pillai JB, Isbatan A, Imai S, Gupta MP. Poly (adp-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by nad1 depletion and reduced sir2alpha deacetylase activity. J Biol Chem 2005;280:43121-43130.